文献速递肝病

系统综述与Meta分析:代谢功能障碍相关脂肪性肝病中脂肪变严重程度与亚临床动脉粥样硬化的关系

Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-07

该研究检索四个数据库1950年至2023年4月的文献,纳入19项影像学研究共147,411名无既往心血管疾病的中年人,发现轻度脂肪变者亚临床动脉粥样硬化合并OR为1.27,中重度脂肪变者升至1.68,提示肝脏脂肪定量有助于MASLD患者心血管风险分层。

要点

  • 轻度脂肪变与亚临床动脉粥样硬化相关,合并OR为1.27(95%CI 1.13-1.41)。
  • 中重度脂肪变关联更强,合并OR为1.68(95%CI 1.41-2.00)。
  • 肝脏脂肪定量可能增强MASLD患者心血管风险分层。

核心结论

  • 即使轻度脂肪变也与心血管疾病风险相关,且脂肪变严重程度进一步强化这一关联。
  • 这些发现提示肝脏脂肪定量可增强MASLD患者的心血管疾病风险分层。

研究设计与样本

  • 系统综述与Meta分析,检索四个数据库1950年至2023年4月的文献。
  • 纳入19项采用影像学评估脂肪变程度与亚临床动脉粥样硬化关系的研究。
  • 共纳入147,411名无既往心血管疾病的中年人,男性占74.94%,平均年龄45.53岁(SD 10.69),平均BMI 24.3 kg/m2(SD 3.35)。
  • 使用纽卡斯尔-渥太华量表进行质量评估,采用DerSimonian-Liard随机效应模型进行Meta分析,并进行亚组分析验证。

主要发现

  • 轻度脂肪变者亚临床动脉粥样硬化的合并OR为1.27(95%CI 1.13-1.41,I2=76.68%)。
  • 中重度脂肪变者亚临床动脉粥样硬化的合并OR显著升高至1.68(95%CI 1.41-2.00,I2=89.02%)。
  • 聚焦高质量研究的敏感性分析一致支持该发现,亚组分析结果保持稳健。
  • Meta回归显示较高的平均AST和ALT以及较低的平均HDL是该关联的显著调节因素。

临床怎么用

  • 原文结论认为肝脏脂肪定量可增强MASLD患者的心血管疾病风险分层。

局限性

  • 轻度脂肪变合并OR的异质性I2=76.68%。
  • 中重度脂肪变合并OR的异质性I2=89.02%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent liver condition recognised as an independent risk factor for cardiovascular disease (CVD). However, there is ongoing debate regarding the effective strategy for cardiovascular risk assessment in MASLD. AIM: To investigate the relationship between liver imaging, specifically focusing on the severity of steatosis and subclinical atherosclerosis. METHODS: We conducted a thorough search across four databases, from 1950 to April 2023, to identify eligible studies employing imaging to explore the relationship between different degrees of steatosis and subclinical atherosclerosis among MASLD. Additionally, we conducted a quality assessment using the Newcastle Ottawa Scale, performed a meta-analysis employing the DerSimonian-Liard random-effects model, and conducted subgroup analyses for validation. RESULTS: In total, 19 studies, encompassing 147,411 middle-aged individuals without previous CVD (74.94% male; mean age 45.53 years [SD 10.69]; mean BMI 24.3 kg/m2 [SD 3.35]), were included. The pooled odds ratio for subclinical atherosclerosis was 1.27 (95% CI: 1.13-1.41, I2 = 76.68%) in mild steatosis and significantly increased to 1.68 (95% CI: 1.41-2.00, I2 = 89.02%) in moderate to severe steatosis. Sensitivity analysis, focusing on high-quality studies, consistently supported this finding and the results remained robust across subgroup analyses. Furthermore, meta-regression revealed that a higher mean AST and ALT, alongside a lower mean HDL, were significant moderators of this association. CONCLUSIONS: Even mild steatosis is associated with CVD risk, and steatosis severity further intensifies this association. These findings suggest that liver fat quantification enhances CVD risk stratification in patients with MASLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jamalinia M, Zare F, Noorizadeh K, et al. Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024. PMID: 38186044. doi:10.1111/apt.17869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。